TITLE:
Formulation and In-Vitro Release Pattern Study of Gliclazide Matrix Tablet
AUTHORS:
Tanbir Ahammad, Marium Begum, A. F. M. Towheedur Rahman, Moynul Hasan, Saikat Ranjan Paul, Shaila Eamen, Md. Iftekhar Hussain, Md. Hazrat Ali, Md. Ashraful Islam, Mohammad Mizanur Rahman, Mamunur Rashid
KEYWORDS:
Gliclazide, Sustained Release, Methocel K15M CR, Methocel K4M CR, In-Vitro Bioequivalence
JOURNAL NAME:
Pharmacology & Pharmacy,
Vol.6 No.3,
March
9,
2015
ABSTRACT: In current decade, pharmaceutical industries of Bangladesh are giving much emphasize on the formulation of time release preparation to treat various chronic diseases in order to decrease the frequency of administration and to improve patient compliance. Objectives: The objective of this investigation is to design and evaluate sustained release matrix tablet of Gliclazide by direct compression method employing polymers of hydroxypropylmethyl cellulose (HPMC) derivatives (K15M CR and K4M CR) and to select the optimized formulations and compression process by performing a comparative release kinetic study with a reference product, Diamicron MR (one of the worldwide brand of Gliclazide sustain released tablet manufactured by Servier one of the French pharmaceutical company) tablet. Methods: Release kinetics of Gliclazide matrix tablets were determined using USP paddle method at Phosphate buffer (pH 7.4). The release mechanism was explored and explained with zero order, first order, Higuchi and Korsmeyer model. Result: It is found that formulation with lower polymeric concentration follows Higuchi release kinetics and that the formulation with higher concentration best fits with zero order release kinetics. Among the formulations, F1 and F6 show almost similar dissolution profile with Diamicron MR Tablet, which can be suitable candidates for further in-vivo bioequivalence study. Conclusion: Findings of this investigation suggest that F1 and F6 formulations are potential candidates for further bioequivalence study among other formulations.